Nasdaq

Design Therapeutics Initiates Phase 1 Trial for DT-216P2; Reports Progress and Financial Results for 2024

Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...
Yahoo Finance

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial ...

CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Nasdaq

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
Morningstar

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, ...
Investing

Design Therapeutics unveils DT-818 for myotonic dystrophy treatment

"Today we are excited to unveil DT-818 as our development candidate for the treatment of DM1, a debilitating neuromuscular disease with significant unmet medical need," said Pratik Shah, chairperson ...